IART SVP granted 15,957 RSUs, shares withheld for tax

INTEGRA LIFESCIENCES HOLDINGS CORP senior vice president and principal accounting officer Jeffrey Mosebrook received a grant of 15,957 restricted stock units on March 11, 2026.

Rhea-AI Filing Summary

INTEGRA LIFESCIENCES HOLDINGS CORP senior vice president and principal accounting officer Jeffrey Mosebrook received a grant of 15,957 restricted stock units on March 11, 2026. These RSUs will vest 33% on the first and second anniversaries of the grant date and 34% on the third anniversary.

To cover tax liabilities, 341 common shares at $9.55 per share on March 10, 2026 and 806 common shares at $9.61 per share on March 11, 2026 were withheld. Following these transactions, Mosebrook directly owns 35,453 common shares and holds 15,957 RSUs.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Mosebrook Jeffrey

Role SVP, Fin & Princ Acct Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	15,957	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	806	$9.61	$8K
Exercise Price or Tax Liability	Common Stock	341	$9.55	$3K

Holdings After Transaction: Restricted Stock Units — 15,957 contracts (Direct); Common Stock — 35,453 shares (Direct)

Footnotes (1)

1. F1. The award was a restricted stock unit award which will vest 33% on the first and second anniversaries and 34% on the third anniversary of the grant date of 3/11/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did INTEGRA LIFESCIENCES (IART) executive Jeffrey Mosebrook report on this Form 4?

Jeffrey Mosebrook reported receiving 15,957 restricted stock units and having 1,147 common shares withheld for taxes. The RSU grant increases his equity-based compensation, while the tax-related share withholdings are routine and not open-market sales.

How many restricted stock units did Jeffrey Mosebrook receive from INTEGRA LIFESCIENCES (IART)?

He received a grant of 15,957 restricted stock units. These RSUs convert into common stock as they vest and represent additional long-term equity compensation tied to his continued service and the company’s performance over the vesting period.

What is the vesting schedule for Jeffrey Mosebrook’s 15,957 RSUs at INTEGRA LIFESCIENCES (IART)?

The 15,957 RSUs vest 33% on the first anniversary, 33% on the second, and 34% on the third anniversary of the March 11, 2026 grant date. This three-year schedule encourages retention and aligns compensation with long-term company results.

Were Jeffrey Mosebrook’s INTEGRA LIFESCIENCES (IART) transactions open-market sales?

No, the 341 and 806 common shares involved were withheld to satisfy tax liabilities. These “F” code transactions are tax-withholding dispositions by the issuer, not discretionary open-market sales, and are common when stock awards vest or are granted.

How many INTEGRA LIFESCIENCES (IART) shares does Jeffrey Mosebrook hold after these transactions?

After the reported transactions, Jeffrey Mosebrook directly owns 35,453 common shares. In addition, he holds 15,957 restricted stock units that will vest over three years, further increasing his potential future ownership if he remains with the company.

At what prices were INTEGRA LIFESCIENCES (IART) shares withheld for Jeffrey Mosebrook’s taxes?

Shares were withheld at $9.55 per share for 341 shares on March 10, 2026, and $9.61 per share for 806 shares on March 11, 2026. These prices reflect the value used to calculate shares needed to cover tax obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/12/2026 - 05:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mosebrook Jeffrey

(Last) (First) (Middle)

1100 CAMPUS ROAD

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Fin & Princ Acct Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		F		341	D	$9.55	36,259	D
Common Stock	03/11/2026		F		806	D	$9.61	35,453	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	03/11/2026		A		15,957		(1)	(1)	Common Stock	15,957	$0	15,957	D

Explanation of Responses:

1. The award was a restricted stock unit award which will vest 33% on the first and second anniversaries and 34% on the third anniversary of the grant date of 3/11/2026.

Remarks:

	/s/ Michael D. Hutchinson; Attorney-in-Fact for Jeffrey Mosebrook	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.